Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias
- Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
- Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
- Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
Martha Gulati: The mission of the ASPC and promoting cardiovascular health
It is an exciting time for preventive cardiology with new therapies and medications being produced and shift in focus to preventing cardiovascular disease. Dr Martha Gulati (President-Elect of the American Society for Preventive Cardiology [ASPC]) reveals how the society are helping to communicate these developments and provide more practical resources and information. She is looking […]
Martha Gulati: What can we look forward to at the American Society for Preventive Cardiology 2022 Congress?
Dr Martha Gulati (President-Elect of the American Society for Preventive Cardiology [ASPC]) provides a sneak peak into the exciting programme at the ASPC 2022 Congress on CVD Prevention on 29th – 31st July in Kentucky, USA. The meeting theme is the ‘ABCs of prevention’, and aims to raise awareness of the many ways in which […]
Martha Gulati: The importance of heart disease awareness and prevention
Heart disease is the leading cause of death for women in the USA but so many are unaware of this prevalence. Dr Martha Gulati (President-Elect of the American Society for Preventive Cardiology) provides her advice regarding knowing the signs of heart disease, recognizing whether you are at risk and taking the necessary actions to help […]
Dylan Steen, ACC 2022: SuperWIN: A multisite randomized, controlled trial of a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction
The SuperWIN study is a supermarket and web-based intervention targeting nutrition. touchCARDIO spoke to Prof Dylan Steen (University of Cincinnati Medical Center, Cincinnati, OH, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘SuperWIN: A Multisite, Randomized, Controlled Trial of a Supermarket and Web-based Intervention Targeting Nutrition For Cardiovascular […]
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy
Heart International. 2022;16(2):91–8 DOI: https://doi.org/10.17925/HI.2022.16.2.91
Hypertrophic cardiomyopathy (HCM), along with its more common subgroup, hypertrophic obstructive cardiomyopathy (HOCM), is the most common monogenic cardiovascular disorder, with a prevalence of about 1 in 500,1 and a dominant inheritance pattern, thus clustering in affected families. Patients with HCM often have significant limitations to their exercise capacity, and while there are several underlying pathomechanisms for […]
Effect of Endothelial Adhesion Molecules on Atrial Fibrillation: A Systematic Review and Meta-analysis
Heart International 2022;16(2):75–84 DOI: https://doi.org/10.17925/HI.2022.16.2.75
Atrial fibrillation (AF), one of the most common cardiac arrhythmias, is considered to be a significant risk factor for cardiovascular disease, stroke and mortality. The prevalence of AF increases with age, and patients with AF are at risk of atrial thrombosis and its consequences.1 The pathogenesis of AF consists of inflammatory activity, structural remodelling and endothelial […]
High-power Short-duration Radiofrequency Ablation for Atrial Fibrillation: A Clinical Review
European Journal of Arrhythmia & Electrophysiology. 2022;8(1):13-9 DOI: https://doi.org/10.17925/EJAE.2022.8.1.13
Atrial fibrillation (AF) is the most common type of treated cardiac arrhythmia. The prevalence of the condition increases with age, and it presents with a wide spectrum of symptoms and severity. As the population ages, particularly in developed countries, the burden of AF increases.1 Compared with sinus rhythm, AF is also associated with an increased incidence of […]
COVID-19 and Myocarditis: Review of Clinical Presentations, Pathogenesis and Management
Heart International. 2022;16(1):20–7 DOI: https://doi.org/10.17925/HI.2022.16.1.20
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2), has been associated with several cardiovascular disease manifestations, including acute coronary syndromes, arrhythmias, heart failure, thromboembolic complications and myocardial injury.1 Myocardial injury, defined as elevation in serum cardiac troponin levels, can occur with myocarditis, stress cardiomyopathy and microvascular thrombosis, and is associated with […]
Low-flow, Low-gradient Severe Aortic Stenosis: A Review
Heart International. 2023;17(1):Online ahead of journal publication
The global prevalence of aortic stenosis (AS) has steadily increased over the past several decades.1 In high-income countries, degenerative calcific aortic valve disease is the primary aetiology for AS, whereas chronic rheumatic valve disease and infective endocarditis remain more common causes worldwide.2 Population-wide trends in developed countries suggest a strong relationship between advanced age and incidence of […]
Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention
Heart International. 2022;16(2):105–11 DOI: https://doi.org/10.17925/HI.2022.16.2.105
In recent years, patients undergoing non-emergent percutaneous coronary intervention (PCI) procedures have become increasingly older, with a more significant comorbidity burden and complex coronary disease.1 Many of the patients who undergo elective or urgent PCI are surgical turndown patients, for whom PCI is the only revascularization option.2 For these high-risk patients, more interventionalists are opting for […]
Can Percutaneous Coronary Intervention Revive a Failing Heart?
Heart International. 2022;16(2):72–4 DOI: https://doi.org/10.17925/HI.2022.16.2.72
Percutaneous coronary intervention (PCI) has evolved considerably in both technique and technology since Andreas Grüntzig first intervened on a focal, proximal lesion in the left anterior descending artery in 1977.1 While this has resulted in increasingly complex anatomical subsets being treated, contemporary trials of PCI in patients with stable coronary artery disease (CAD) have continued to […]
FOREWORD – HEART INTERNATIONAL – VOLUME 16 ISSUE 2 – 2022
Welcome to the latest issue of Heart International. Cardiovascular science continues to evolve at an impressive rate, and the range of articles presented here highlights cutting-edge technology and innovation within cardiology. We begin with a commentary by Divaka Perera on the REVIVED study, which evaluated whether percutaneous coronary intervention could improve outcomes in patients with […]
Want To Know More About Our Journal?
Taking a balanced and practical view of the current clinical landscape in Cardio is at the heart of touchCARDIO and the journal we produce.
The European Journal of Arrhythmia & Electrophysiology and Heart International are double-blind peer reviewed by at least two independent experts in the field to ensure articles are balanced, objective and relevant to the day-to-day clinical setting.
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!